{"classes":[{"categories":[{"measurements":[{"comment":"OS median and 90% CI were not estimable due to insufficient number of events.","groupId":"OG000","lowerLimit":"5.2","upperLimit":"NA","value":"NA"},{"comment":"OS median and 90% CI were not estimable due to insufficient number of events.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"OS median and 90% CI were not estimable due to insufficient number of events.","groupId":"OG002","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"OS median and 90% CI were not estimable due to insufficient number of events.","groupId":"OG003","lowerLimit":"5.4","upperLimit":"NA","value":"NA"},{"comment":"OS median and 90% CI were not estimable due to insufficient number of events.","groupId":"OG004","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"OS median and 90% CI were not estimable due to insufficient number of events.","groupId":"OG005","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"OS median and 90% CI were not estimable due to insufficient number of events.","groupId":"OG006","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"OS median and 90% CI were not estimable due to insufficient number of events.","groupId":"OG007","lowerLimit":"6.3","upperLimit":"NA","value":"NA"},{"comment":"OS median and 90% CI were not estimable due to insufficient number of events.","groupId":"OG008","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"OS median and 90% CI were not estimable due to insufficient number of events.","groupId":"OG009","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"OS median and 90% CI were not estimable due to insufficient number of events.","groupId":"OG010","lowerLimit":"5.1","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"13"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"26"},{"groupId":"OG007","value":"9"},{"groupId":"OG008","value":"20"},{"groupId":"OG009","value":"14"},{"groupId":"OG010","value":"19"}],"units":"Participants"}],"description":"Time from first dose of study drug to date of death due to any cause. Participants who were still alive or who were lost to follow-up will be censored at the date of last contact.","dispersionType":"90% Confidence Interval","groups":[{"description":"Dose escalation of rebastinib 50 mg BID PO in combination with paclitaxel administered by IV infusion at 80 mg/m\\^2 on days 1, 8, and 15 of repeated 28-day cycles.","id":"OG000","title":"Part 1 Arm 1 Rebastinib 50 mg + Paclitaxel 80 mg/m^2"},{"description":"Dose escalation of rebastinib 100 mg BID PO in combination with paclitaxel IV infusion at 80 mg/m\\^2 on days 1, 8, and 15 of repeated 28-day cycles.","id":"OG001","title":"Part 1 Arm 2 Rebastinib 100 mg + Paclitaxel 80 mg/m^2"},{"description":"Dose expansion in TNBC. Rebastinib 50 mg BID PO in combination with paclitaxel IV infusion at 80 mg/m\\^2 on days 1, 8, and 15 of repeated 28-day cycles.","id":"OG002","title":"Part 2 Cohort 1 Rebastinib 50 mg + Paclitaxel 80 mg/m^2"},{"description":"Dose expansion in TNBC. Rebastinib 100 mg BID PO in combination with paclitaxel IV infusion at 80 mg/m\\^2 on days 1, 8, and 15 of repeated 28-day cycles.","id":"OG003","title":"Part 2 Cohort 1 Rebastinib 100 mg + Paclitaxel 80 mg/m^2"},{"description":"Dose expansion in inflammatory breast cancer. Rebastinib 50 mg BID PO in combination with paclitaxel IV infusion at 80 mg/m\\^2 on days 1, 8, and 15 of repeated 28-day cycles.","id":"OG004","title":"Part 2 Cohort 2 Rebastinib 50 mg + Paclitaxel 80 mg/m^2"},{"description":"Dose expansion in inflammatory breast cancer. Rebastinib 100 mg BID PO in combination with paclitaxel IV infusion at 80 mg/m\\^2 on days 1, 8, and 15 of repeated 28-day cycles.","id":"OG005","title":"Part 2 Cohort 2 Rebastinib 100 mg + Paclitaxel 80 mg/m^2"},{"description":"Dose expansion in ovarian cancer. Rebastinib 50 mg BID PO in combination with paclitaxel IV infusion at 80 mg/m\\^2 on days 1, 8, and 15 of repeated 28-day cycles.","id":"OG006","title":"Part 2 Cohort 3 Rebastinib 50 mg + Paclitaxel 80 mg/m^2"},{"description":"Dose expansion in ovarian cancer. Rebastinib 100 mg BID PO in combination with paclitaxel IV infusion at 80 mg/m\\^2 on days 1, 8, and 15 of repeated 28-day cycles.","id":"OG007","title":"Part 2 Cohort 3 Rebastinib 100 mg + Paclitaxel 80 mg/m^2"},{"description":"Dose expansion in endometrial cancer. Rebastinib 50 mg BID PO in combination with paclitaxel IV infusion at 80 mg/m\\^2 on days 1, 8, and 15 of repeated 28-day cycles.","id":"OG008","title":"Part 2 Cohort 4 Rebastinib 50 mg + Paclitaxel 80 mg/m^2"},{"description":"Dose expansion in endometrial cancer. Rebastinib 100 mg BID PO in combination with paclitaxel IV infusion at 80 mg/m\\^2 on days 1, 8, and 15 of repeated 28-day cycles.","id":"OG009","title":"Part 2 Cohort 4 Rebastinib 100 mg + Paclitaxel 80 mg/m^2"},{"description":"Dose expansion in gynecological carcinosarcoma (GCS). Rebastinib 50 mg BID PO in combination with paclitaxel IV infusion at 80 mg/m\\^2 on days 1, 8, and 15 of repeated 28-day cycles.","id":"OG010","title":"Part 2 Cohort 5 Rebastinib 50 mg + Paclitaxel 80 mg/m^2"}],"paramType":"MEDIAN","populationDescription":"mITT participants that were evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"First Dose of Study Drug to Death due to Any Cause (Up to 2.82 years)","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"months"}